An ERCC4 regulatory variant predicts grade‐3 or ‐4 toxicities in patients with advanced non‐small cell lung cancer treated by platinum‐based therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|142|6|1218-1229

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.142, Iss.6, 2018-03, pp. : 1218-1229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

By  

Current Medical Imaging Reviews, Vol. 11, Iss. 4, 2015-01 ,pp. : 218-227

Bentham Science Publishers

Access to resources Recommend Favorite

Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 665-670

Karger

Access to resources Recommend Favorite

Non-Platinum-Based First-Line Followed by Platinum-Based Second-Line Chemotherapy or the Reverse Sequence in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis by the Lung Cancer Group of the Hellenic Oncology Research Group

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 229-236

Karger

Access to resources Recommend Favorite

Platinum-Based, Leukocyte-Depleting Chemotherapy Does Not Alter Induced Sputum Markers of Neutrophilic Inflammation in COPD Patients with Unresectable Non-Small Cell Lung Cancer

By  

Respiration, Vol. 70, Iss. 2, 2003-05 ,pp. : 166-171

Karger

Access to resources Recommend Favorite

EML4-ALK Rearrangement and Its Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 83, Iss. 5, 2012-09 ,pp. : 248-256

Karger

Access to resources Recommend Favorite